These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 21273104)

  • 1. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.
    Yan Y; Li Y; Zhang S; Ai C
    J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
    Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
    Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
    Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
    Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
    Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
    J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular model of the alpha(IIb)beta(3) integrin.
    Feuston BP; Culberson JC; Hartman GD
    J Med Chem; 2003 Dec; 46(25):5316-25. PubMed ID: 14640540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding site analysis of CCR2 through in silico methodologies: docking, CoMFA, and CoMSIA.
    Kothandan G; Gadhe CG; Madhavan T; Cho SJ
    Chem Biol Drug Des; 2011 Jul; 78(1):161-74. PubMed ID: 21294847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
    Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
    Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
    Zhou YJ; Zhu LP; Tang Y; Ye DY
    Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic pharmacophore-based molecules as novel integrin alphavbeta3 antagonists. Part IV: preliminary control of alphavbeta3 selectivity by meta-oriented substitution.
    Kubota D; Ishikawa M; Ishikawa M; Yahata N; Murakami S; Fujishima K; Kitakaze M; Ajito K
    Bioorg Med Chem; 2006 Jun; 14(12):4158-81. PubMed ID: 16504518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD; Hamza A; Liu J; Zhan CG
    J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrete functional motifs reside within the cytoplasmic tail of alphaV integrin subunit.
    Haas TA
    Thromb Haemost; 2008 Jan; 99(1):96-107. PubMed ID: 18217140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
    Du J; Qin J; Liu H; Yao X
    J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain.
    Kothandan G; Gadhe CG; Madhavan T; Choi CH; Cho SJ
    Eur J Med Chem; 2011 Sep; 46(9):4078-88. PubMed ID: 21723648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 3D-QSAR modeling and molecular docking study on quinoline derivatives as inhibitors of P-selectin.
    Zeng H; Cao R; Zhang H
    Chem Biol Drug Des; 2009 Dec; 74(6):596-610. PubMed ID: 19843078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of new fused benzazepine as selective dopamine D3 receptor antagonists using 3D-QSAR, molecular docking and molecular dynamics.
    Liu J; Li Y; Zhang S; Xiao Z; Ai C
    Int J Mol Sci; 2011 Feb; 12(2):1196-221. PubMed ID: 21541053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
    Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.